Faeth Therapeutics, Inc.
FTH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FTH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FTH
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing PIKTOR, a small-molecule inhibitor, for advanced endometrial cancer and HR+/HER2- advanced breast cancer, with ongoing Phase 2 and Phase 1b/2 trials.
Key risk: Clinical development uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Faeth Therapeutics, Inc..
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing PIKTOR, a small-molecule inhibitor, for advanced endometrial cancer and HR+/HER2- advanced breast cancer, with ongoing Phase 2 and Phase 1b/2 trials.
- As of June 30, 2026, Faeth had cash and equivalents of $26.9M, net income of -$16.0M, and shareholders' equity of $18.6M [sec].
- The company is advancing PIKTOR through a Phase 2 trial in advanced endometrial cancer (Study FTH-PIK-201) and a Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101) [sec_mda · as of 2026-08-04].
- As of June 30, 2026, Faeth reported an accumulated deficit of $469.4 million [sec_mda · as of 2026-08-04].
- Management expects existing cash to fund operations through topline data readouts from both ongoing PIKTOR trials [sec_mda · as of 2026-08-04].
What works
- PIKTOR is being evaluated in two clinical trials targeting significant cancer indications (advanced endometrial cancer and HR+/HER2- advanced breast cancer), offering potential for multiple data readouts [sec_mda · as of 2026-08-04].
- The company has sufficient cash runway to reach topline data from both ongoing studies, reducing near-term financing risk [sec_mda · as of 2026-08-04].
What to weigh
- Faeth has a history of significant operating losses and an accumulated deficit of $469.4 million as of June 30, 2026, with no product revenue [sec_mda · as of 2026-08-04].
- The company faces substantial uncertainty regarding the timing and cost of completing clinical development and achieving regulatory approval for PIKTOR [sec_mda · as of 2026-05-15].
- Cash and equivalents of $26.9M as of June 30, 2026, are relatively low compared to the accumulated deficit and ongoing trial expenses, though management expects it to cover data readouts [sec] [sec_mda · as of 2026-08-04].
From the filings
Quoted directly from source documents.
Accumulated deficit as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $469.4 million.”
SEC MD&A · August 4, 2026
Cash runway through topline data readouts
“We expect our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements through topline data readouts from both our ongoing Phase 2 trial of PIKTOR in advanced endometrial cancer (Study FTH-PIK-201) and our recently initiated Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer (Study FTH-PIK-101).”
SEC MD&A · August 4, 2026
Risks & what to watch (3)›
Key risks
- Clinical development uncertainty — The company cannot reasonably estimate the timing or cost to complete development of PIKTOR, with risks including trial duration and regulatory outcomes [sec_mda · as of 2026-05-15].
- Substantial accumulated deficit — Accumulated deficit of $469.4M as of June 30, 2026, with ongoing net losses and no product revenue [sec_mda · as of 2026-08-04].
- Limited cash runway beyond data — Cash of $26.9M as of June 30, 2026, may be insufficient beyond topline data readouts, requiring future financing [sec] [sec_mda · as of 2026-08-04].
What to watch
- Topline data readouts from the Phase 2 trial of PIKTOR in advanced endometrial cancer (Study FTH-PIK-201) [sec_mda · as of 2026-08-04].
- Topline data readouts from the Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer (Study FTH-PIK-101) [sec_mda · as of 2026-08-04].
- Any updates on the company's cash position or additional financing activities [sec].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Faeth Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Faeth Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
34.3 months
D/E 0.06 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
49 buys · 29 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
28
Total value held
$45.6M
| Holder | Shares | Value |
|---|---|---|
| woodline partners lp | 361,010 | $11.4M |
| stempoint capital lp | 265,746 | $8.4M |
| millennium management llc | 146,565 | $4.6M |
| franklin resources inc | 133,506 | $4.2M |
| caligan partners lp | 126,002 | $4.0M |
| marshall wace, llp | 65,730 | $2.1M |
| goldman sachs group inc | 61,568 | $1.9M |
| suvretta capital management, llc | 34,549 | $1.1M |
| bank of america corp /de/ | 33,025 | $1.0M |
| renaissance technologies llc | 32,041 | $1.0M |
Showing top 10 of 28 institutional holders of Faeth Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 88.5%
- Days to cover
- 19.6
- Shares short
- 834,411
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FTH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Faeth Therapeutics, Inc.?
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing PIKTOR, a small-molecule inhibitor, for advanced endometrial cancer and HR+/HER2- advanced breast cancer, with ongoing Phase 2 and Phase 1b/2 trials.
Who is the CEO of Faeth Therapeutics, Inc.?
Mr. Anand Parikh Esq., J.D. is the chief executive officer of Faeth Therapeutics, Inc. (FTH).
Where is Faeth Therapeutics, Inc. headquartered?
Faeth Therapeutics, Inc. (FTH) is headquartered in Rockville, MD, United States.
What therapeutic areas does Faeth Therapeutics, Inc. focus on?
Faeth Therapeutics, Inc. develops therapies across Oncology, Nephrology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.